Clinical Trials Directory

Trials / Completed

CompletedNCT04718922

Chlorhexidine Mouthrinse Before EBUS-TBNA

Effect of Chlorhexidine Mouthrinse on Prevention of Microbial Contamination During EBUS-TBNA: a Randomized Clinical Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
112 (actual)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate whether chlorhexidine mouthrinse is effective in preventing microbial contamination during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).

Detailed description

EBUS-TBNA using the convex probe is a standard of care for the assessment of mediastinal and hilar lymphadenopathy. Although EBUS-TBNA is a minimally invasive procedure, rare but serious infectious complications such as pneumonia, lung abscess, empyema, mediastinal adenitis/abscess, mediastinitis, pericarditis, and sepsis were reported. EBUS-scope might be contaminated with oropharyngeal commensal bacteria while passing the oropharyngeal airway during EBUS-TBNA. Contamination of punctured lymph nodes by oropharyngeal commensal bacteria can cause severe infections. Chlorhexidine gluconate is an antimicrobial agent that has a broad antibacterial activity including both gram-positive and negative bacteria. Chlorhexidine has been widely used for surgical scrub, skin disinfection, and mouthrinse. We, therefore, designed a phase 4, single-center, randomized, controlled clinical trial to investigate whether chlorhexidine mouthrinse is effective in preventing microbial contamination during EBUS-TBNA.

Conditions

Interventions

TypeNameDescription
DRUGChlorhexidine Gluconate 0.12 % MouthwashIntervention with chlorhexidine mouthrinse will be performed approximately 10 min before the start of EBUS-TBNA

Timeline

Start date
2021-01-20
Primary completion
2021-06-11
Completion
2021-12-11
First posted
2021-01-22
Last updated
2022-02-15

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04718922. Inclusion in this directory is not an endorsement.